Specialists of the domestic pharmaceutical company Farmak have developed and brought to market a drug for the treatment of severe conditions, chronic cerebrovascular disorders and mental activity disorders – Gliaton (choline alfoscerate). The new drug is produced in the form of a solution for injection in 1000 mg ampoules No. 5.
Farmak is actively working in the sphere of treatment of cardiovascular diseases. In particular, much attention is given to ensure comprehensive effective and affordable treatment of severe and chronic cerebrovascular disorders and mental activity disorders. To achieve this objective, the company’s specialists have developed and brought to market the drug product Gliaton (choline alfoscerate).
Gliaton is indicated in the acute phase of craniocerebral trauma, in impaired consciousness, coma, focal hemispheric symptoms; degenerative involutional psychoorganic syndromes, cerebrovascular insufficiency; primary and secondary mental disorders, memory impairment, confusion and disorientation. The drug is also indicated in emotional instability, irritability, indifference; pseudo melancholy in the elderly.
Gliaton is the drug that “awakens” (brings) patients out of comas, improves patients’ quality of life: improves memory, mental activity after injuries or as a result of cerebrovascular insufficiency.
The course of treatment with the drug is 2-3 weeks.
